UTHR - United Therapeutics Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
126.700
+1.670 (+1.34%)
As of 11:47AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close125.030
Open125.340
Bid126.760 x 800
Ask126.860 x 800
Day's Range124.680 - 127.300
52 Week Range100.570 - 152.550
Volume155,198
Avg. Volume337,965
Market Cap5.519B
Beta1.22
PE Ratio (TTM)7.82
EPS (TTM)16.205
Earnings DateOct 23, 2018 - Oct 29, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est124.90
Trade prices are not sourced from all markets
  • Why Vertex Is Expected to Report Robust EPS Growth in 2018
    Market Realist5 days ago

    Why Vertex Is Expected to Report Robust EPS Growth in 2018

    How Is Vertex Pharmaceuticals Positioned in August? In its Q2 2018 earnings conference call, Vertex Pharmaceuticals (VRTX) reiterated its projection for non-GAAP combined selling, general, and administrative (or SG&A) and research and development (or R&D) expenses to come in in the range of $1.5 billion and $1.55 billion for fiscal 2018. In Q2 2018, the company reported non-GAAP combined R&D and SG&A expenses close to $388 million.

  • Vertex Pharmaceuticals Is Expected to See Robust Revenue Growth
    Market Realist5 days ago

    Vertex Pharmaceuticals Is Expected to See Robust Revenue Growth

    In its Q2 2018 earnings conference call, Vertex Pharmaceuticals (VRTX) updated its revenue guidance for fiscal 2018 from the previously projected range of $2.65 billion–$2.8 billion to $2.9 billion–$3.0 billion. The midpoint of this guidance range would imply a 36% year-over-year (or YoY) rise in revenues in fiscal 2018. This expectation has mainly been driven by the solid adoption of Symdeko since its launch in US markets. The company has not assumed the impact of securing new reimbursement for its CF drugs in markets outside the US in its fiscal 2018 revenue guidance.

  • PR Newswire13 days ago

    United Therapeutics Announces Settlement Of Patent Litigation With Watson Laboratories, Inc. Relating To Tyvaso

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Aug. 8, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it has entered into a Settlement Agreement with Watson ...

  • PR Newswire13 days ago

    United Therapeutics Announces FREEDOM-EV Study Of Orenitram Meets Primary Endpoint

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 8, 2018 /PRNewswire/ -- United Therapeutics Corporation (UTHR) today announced that preliminary analysis indicates that the FREEDOM-EV clinical study of Orenitram® (treprostinil) extended-release tablets in patients suffering from pulmonary arterial hypertension (PAH) has met its primary endpoint of delayed time to first clinical worsening event. Orenitram, when taken with an oral PAH background therapy, decreased the risk of a morbidity/mortality event versus placebo by 26% (p=0.0391). Efficacy was observed across the following key subgroups: age, gender, World Health Organization (WHO) functional class, PAH etiology and background PAH therapy.

  • PR Newswire14 days ago

    United Therapeutics Corporation To Present At 2018 Wedbush PacGrow Healthcare Conference

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Aug. 7, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that James Edgemond , Chief Financial Officer and Treasurer ...

  • ACCESSWIRE15 days ago

    Today's Research Reports on Trending Tickers: Portola Pharmaceuticals and United Therapeutics

    NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Major U.S. markets closed higher on Friday and ended the week on a positive note, as outstanding corporate earnings offsets ongoing trade spats. The Dow Jones ...

  • United Therapeutics: Analyst Recommendations, Product Performance
    Market Realist18 days ago

    United Therapeutics: Analyst Recommendations, Product Performance

    In the second quarter of 2018, United Therapeutics’ Remodulin generated revenues of $159.5 million compared to $157.7 million in the second quarter of 2017, reflecting a 1% YoY (year-over-year) growth.

  • How United Therapeutics Fared in the Second Quarter of 2018
    Market Realist18 days ago

    How United Therapeutics Fared in the Second Quarter of 2018

    In the second quarter of 2018, United Therapeutics (UTHR) generated revenues of $444.5 million compared to $444.6 million in the second quarter of 2017. Its net revenues remained flat YoY (year-over-year), but there was an increase in the number of patients being treated with United Therapeutics’ therapies. In the second quarter of 2018, United Therapeutics reported net income of $172.9 million compared to a net loss of $56 million in the second quarter of 2017.

  • United Therapeutics (UTHR) Q2 Earnings Flat Y/Y, Shares Dip
    Zacks19 days ago

    United Therapeutics (UTHR) Q2 Earnings Flat Y/Y, Shares Dip

    United Therapeutics (UTHR) reports unimpressive second-quarter earnings. Sales rise sequentially. Shares sink 5%.

  • How Is Merck’s Cardiovascular Portfolio Positioned after H1 2018?
    Market Realist20 days ago

    How Is Merck’s Cardiovascular Portfolio Positioned after H1 2018?

    In the second quarter of 2018, Merck’s (MRK) Zetia generated revenues of $226.0 million compared to $367.0 million in the second quarter of 2017, reflecting a ~38% year-over-year (or YoY) decline and a ~26% sequential decline. In the second quarter of 2018, in the US and international markets (outside the US markets), Zetia generated revenues of $8.0 million and $218.0 million, respectively, compared to $122.0 million and $246.0 million in the second quarter of 2017.

  • Thomson Reuters StreetEvents20 days ago

    Edited Transcript of UTHR earnings conference call or presentation 1-Aug-18 1:00pm GMT

    Q2 2018 United Therapeutics Corp Earnings Call

  • United Therapeutics (UTHR) Tops Q2 Earnings and Revenue Estimates
    Zacks20 days ago

    United Therapeutics (UTHR) Tops Q2 Earnings and Revenue Estimates

    United Therapeutics (UTHR) delivered earnings and revenue surprises of 29.76% and 27.27%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press20 days ago

    United Therapeutics: 2Q Earnings Snapshot

    On a per-share basis, the Silver Spring, Maryland-based company said it had net income of $3.98. Earnings, adjusted for stock option expense, were $4.36 per share. The results surpassed Wall Street expectations. ...

  • PR Newswire20 days ago

    United Therapeutics Corporation Reports Second Quarter 2018 Financial Results

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Aug. 1, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the quarter ended June 30, 2018. ...

  • FDA Approves United Therapeutics’ Implantable System for Remodulin
    Market Realist21 days ago

    FDA Approves United Therapeutics’ Implantable System for Remodulin

    Today, the FDA approved United Therapeutics’ (UTHR) new drug application for its Implantable System for Remodulin (or ISR).

  • Medtronic Receives FDA Approval for Implantable System for Remodulin® to Treat Patients with Pulmonary Arterial Hypertension
    GlobeNewswire21 days ago

    Medtronic Receives FDA Approval for Implantable System for Remodulin® to Treat Patients with Pulmonary Arterial Hypertension

    Medtronic SynchroMed(TM) II Pump, Proprietary Catheter  Deliver United Therapeutics` Remodulin® (treprostinil) Injection DUBLIN - July 31, 2018 - Medtronic plc (NYSE:MDT) has received U.S. Food and Drug ...

  • GlobeNewswire21 days ago

    SteadyMed Shareholders Approve Proposed Acquisition by United Therapeutics

    SteadyMed Ltd. (STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that SteadyMed shareholders voted to approve the previously announced acquisition of the company by United Therapeutics Corporation (UTHR) at an extraordinary general meeting of shareholders held on July 30, 2018. Upon completion of the acquisition, SteadyMed shareholders will be entitled to receive $4.46 per share in cash and one contractual contingent value right per share (subject to the Contingent Value Rights Agreement), which will represent the right to receive $2.63 in cash upon the achievement of a milestone related to the commercialization of Trevyent®.

  • PR Newswire21 days ago

    United Therapeutics Announces FDA Approval Of The Implantable System For Remodulin®

    The ISR has been developed under a collaboration with Medtronic (MDT). In December 2017, Medtronic received FDA approval of a premarket application (PMA) for a proprietary intravascular infusion catheter to be used with its SynchroMed™ II implantable infusion pump and related infusion system components (together referred to as the Implantable System for Remodulin) in order to deliver Remodulin for the treatment of pulmonary arterial hypertension (PAH).

  • PR Newswire26 days ago

    United Therapeutics Corporation To Report Second Quarter 2018 Financial Results Before The Market Opens On Wednesday, August 1, 2018

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , July 26, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will report its second quarter 2018 financial ...

  • See what the IHS Markit Score report has to say about United Therapeutics Corp.
    Markit28 days ago

    See what the IHS Markit Score report has to say about United Therapeutics Corp.

    United Therapeutics Corp NASDAQ/NGS:UTHR

  • GlobeNewswirelast month

    HSR Act Waiting Period Terminated for United Therapeutics’ Acquisition of SteadyMed Ltd.

    As previously announced on April 30, 2018, United Therapeutics and SteadyMed entered into a definitive merger agreement under which United Therapeutics will acquire SteadyMed for $4.46 per share in cash at closing and one contractual contingent value right per share (subject to the Contingent Value Rights Agreement), which will represent the right to receive $2.63 in cash upon the achievement of a milestone related to the commercialization of Trevyent®. The termination of the waiting period under the HSR Act satisfies one of the conditions to closing of the acquisition, which remains subject to other closing conditions, including the approval of the acquisition by SteadyMed’s shareholders. A meeting of SteadyMed’s shareholders to vote upon the acquisition will be held on July 30, 2018.

  • PR Newswirelast month

    HSR Act Waiting Period Terminated for United Therapeutics' Acquisition of SteadyMed Ltd.

    As previously announced on April 30, 2018, United Therapeutics and SteadyMed entered into a definitive merger agreement under which United Therapeutics will acquire SteadyMed for $4.46 per share in cash at closing and one contractual contingent value right per share (subject to the Contingent Value Rights Agreement), which will represent the right to receive $2.63 in cash upon the achievement of a milestone related to the commercialization of Trevyent®. The termination of the waiting period under the HSR Act satisfies one of the conditions to closing of the acquisition, which remains subject to other closing conditions, including the approval of the acquisition by SteadyMed's shareholders. A meeting of SteadyMed's shareholders to vote upon the acquisition will be held on July 30, 2018.

  • GlobeNewswire2 months ago

    Factors of Influence in 2018, Key Indicators and Opportunity within Dr Pepper Snapple Group, United Therapeutics, Universal Health Realty Income Trust, Forestar Group, Schlumberger, and Thermo Fisher Scientific — New Research Emphasizes Economic Growth

    NEW YORK, June 25, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Dr ...

  • Is United Therapeutics Corporation’s (NASDAQ:UTHR) ROE Of 20.42% Sustainable?
    Simply Wall St.2 months ago

    Is United Therapeutics Corporation’s (NASDAQ:UTHR) ROE Of 20.42% Sustainable?

    This article is intended for those of you who are at the beginning of your investing journey and want to begin learning the link between United Therapeutics Corporation (NASDAQ:UTHR)’s returnRead More...